MedTrace Logo

Retrospective Study on the Incidence and Management of Anemia in Oncology

NCT04779840 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 349

Last updated 2021-03-03

No results posted yet for this study

Summary

The incidence of anemia ranges from 20 to 75% depending on the type of cancer. It is often present at diagnosis and increases with specific treatments. It has an impact on overall survival and quality of life. Its origins are multiple (pure iron deficiency or functional, malnutrition, dyserythropoiesis, insufficiency renal, hemolysis, chemotherapy, radiotherapy, targeted therapies).

Transfusion is the most common treatment offered in the management of anemia. The incidence of anemia and its consequences are often underestimated during cancer management.

Recommendations were published in 2012. An inventory of the incidence of anemia before and after the publication of these recommendations are proposed in order to assess their impact on daily practice.

Conditions

Interventions

OTHER

anemia assessment

evaluation of anemia status

Sponsors & Collaborators

  • Weprom

    lead OTHER

Principal Investigators

  • Katell LE DÛ, MD · Centre Jean Bernard/Clinique Victor Hugo - LE MANS

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-20
Primary Completion
2021-01-20
Completion
2021-01-20

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04779840 on ClinicalTrials.gov